Yarrow Bioscience Inc (YARW) - Total Liabilities
Based on the latest financial reports, Yarrow Bioscience Inc (YARW) has total liabilities worth $1.24 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See YARW defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Yarrow Bioscience Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Yarrow Bioscience Inc's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Yarrow Bioscience Inc's assets to evaluate the company's liquid asset resilience ratio.
Yarrow Bioscience Inc Competitors by Total Liabilities
The table below lists competitors of Yarrow Bioscience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Perak Transit Bhd
KLSE:0186
|
Malaysia | RM916.85 Million |
|
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
|
USA | $16.70 Million |
|
Huvitz Co. Ltd
KQ:065510
|
Korea | ₩113.72 Billion |
|
Zimmite Taiwan Ltd
TWO:8435
|
Taiwan | NT$140.55 Million |
|
Toivo Group Oyj
HE:TOIVO
|
Finland | €98.63 Million |
|
G5 Entertainment publ AB
ST:G5EN
|
Sweden | Skr109.54 Million |
|
Dominari Holdings Inc.
NASDAQ:DOMH
|
USA | $35.52 Million |
|
EURODRY LTD. DL -01
F:0LQ
|
Germany | €109.59 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Yarrow Bioscience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see YARW current and non-current assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yarrow Bioscience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yarrow Bioscience Inc (2015–2025)
The table below shows the annual total liabilities of Yarrow Bioscience Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.40 Million | -83.84% |
| 2024-12-31 | $14.82 Million | +65.58% |
| 2023-12-31 | $8.95 Million | -6.34% |
| 2022-12-31 | $9.56 Million | -48.09% |
| 2021-12-31 | $18.41 Million | -67.27% |
| 2020-12-31 | $56.25 Million | +427.61% |
| 2019-12-31 | $10.66 Million | +11.62% |
| 2018-12-31 | $9.55 Million | -92.29% |
| 2017-12-31 | $123.90 Million | +73.30% |
| 2016-12-31 | $71.49 Million | +19.48% |
| 2015-12-31 | $59.84 Million | -- |
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based i… Read more